SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
13F holders, Q1 2022
Institutional positions in SAB Biotherapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −9 vs. Q4 2021
- Shares held
- 1.92M
- +96.3K (+5.3%) vs. Q4 2021
- Total value
- $724.0K
- −$2.38M (−76.7%) vs. Q4 2021
- New holders
- 0
- 2 more added
- Sold out
- 9
- 5 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SABSW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $10.5K |
| Q1 2026 | 6 | $21.1K |
| Q4 2025 | 7 | $8.34K |
| Q3 2025 | 10 | $19.5K |
| Q2 2025 | 6 | $26.7K |
| Q1 2025 | 7 | $28.1K |
| Q4 2024 | 9 | $66.3K |
| Q3 2024 | 9 | $22.3K |
| Q2 2024 | 11 | $52.1K |
| Q1 2024 | 12 | $43.8K |
| Q4 2023 | 10 | $38.1K |
| Q3 2023 | 9 | $93.0K |
| Q2 2023 | 10 | $88.4K |
| Q1 2023 | 14 | $51.6K |
| Q4 2022 | 13 | $57.9K |
| Q3 2022 | 16 | $84.0K |
| Q2 2022 | 14 | $262.0K |
| Q1 2022 | 13 | $724.0K |
| Q4 2021 | 22 | $3.10M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding SAB Biotherapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Shaolin Capital Management LLC | 824,999 | $397.0K | 0.01% | −16,796−2.0% | Reduced |
| Balyasny Asset Management LLC | 281,107 | $129.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 150,846 | $72.0K | 0.00% | +119,439+380.3% | Added |
| Yakira Capital Management, Inc. | 108,485 | $52.0K | 0.01% | −7,300−6.3% | Reduced |
| Equitec Proprietary Markets, LLC | 45,000 | $22.0K | 0.01% | 00.0% | Unchanged |
| HRT Financial LP | 44,982 | $20.0K | 0.00% | 00.0% | Unchanged |
| Walleye Capital LLC | 23,258 | $11.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 19,487 | $9.00K | 0.00% | −141−0.7% | Reduced |
| Walleye Trading LLC | 15,505 | $7.00K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 11,322 | $5.00K | 0.00% | −2,228−16.4% | Reduced |
| Tower Research Capital LLC (TRC) | 48 | $0 | 0.00% | 00.0% | Unchanged |
| Radcliffe Capital Management, L.P. | 55,692 | – | – | −25,205−31.2% | Reduced |
| LMR Partners LLP | 337,282 | – | – | +320,982+1,969.2% | Added |
| CVI Holdings, LLC | 0 | $0 | 0.00% | −58,320−100.0% | Sold out |
| Integrity Capital Management (HK) Ltd | 0 | $0 | 0.00% | −54,433−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Rivernorth Capital Management, LLC | 0 | $0 | 0.00% | −46,665−100.0% | Sold out |
| Fort Baker Capital Management LP | 0 | $0 | 0.00% | −36,693−100.0% | Sold out |
| Context Capital Management, LLC | 0 | $0 | 0.00% | −24,203−100.0% | Sold out |
| Bluefin Capital Management, LLC | 0 | $0 | 0.00% | −19,249−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | – | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −2,888−100.0% | Sold out |